An anti-CGRP drip to prevent migraine
Eptinezumab
A drip (infusion) given into a vein every three months to prevent migraine attacks.
What is Eptinezumab?
Eptinezumab (brand name Vyepti) is a newer type of medicine, called an anti-CGRP biologic, used to prevent migraine in people who have frequent attacks. Unlike the others in this group, it is given as a drip (infusion) into a vein, usually once every three months, in a clinic or hospital. It is a preventer, taken regularly to reduce how often migraines happen, so it does not treat an attack that has already started. It works by blocking CGRP, a natural body chemical involved in migraine. It is generally well tolerated, though reactions during or after the infusion, including allergic reactions, can occur. It is usually offered after older preventers have not worked, and it is not recommended in pregnancy without specialist advice.
Education and reference only. This is a plain-language guide to Eptinezumab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Eptinezumab is a laboratory-made antibody, known as a biologic, that targets a body chemical called CGRP (calcitonin gene-related peptide), which plays a key part in migraine attacks. It is used as a preventer, taken regularly to reduce how often migraines happen rather than to stop an attack already underway. It differs from the other anti-CGRP medicines because it is given as a drip into a vein rather than an injection under the skin. In the UK it is usually considered for people with frequent or chronic migraine who have tried older preventers without success.
How it works
During a migraine, levels of CGRP rise and help drive the pain and other symptoms. Eptinezumab attaches to CGRP and stops it acting, which over time reduces how often migraines occur and how severe they are. Because it is given straight into a vein, its effect can begin soon after the first infusion, but it is still a preventer given on a regular three-monthly schedule rather than an acute painkiller. It does not relieve an attack that has already begun, so a separate acute treatment is still needed for breakthrough migraines.
Company & origin
Originated / developed by: Lundbeck.
A newer biologic medicine used in the UK to help prevent migraine in people who have frequent attacks and have tried older preventers.
What it treats
Conditions Eptinezumab is used for
Practical use
How to take Eptinezumab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as a drip (infusion) into a vein, usually once every three months, at a clinic or hospital rather than at home.
- Each infusion takes around half an hour, and you will be watched afterwards for any reaction.
- Take it regularly to prevent migraine; it will not relieve an attack that has already started, so keep using your usual acute treatment as well.
- Allow a few months to judge the overall benefit, even though some people notice improvement sooner.
- Tell your specialist if you are pregnant, planning a pregnancy or breastfeeding, as it should only be used on specialist advice.
Weighing it up
Advantages & disadvantages of Eptinezumab
Advantages
- Given just once every three months, so there are only a few treatments a year.
- Because it goes straight into a vein, some people notice benefit soon after the first infusion.
- Generally well tolerated, with fewer body-wide side effects than some older preventer tablets.
Disadvantages
- It is a preventer only and does not treat an attack that has already begun.
- It must be given as a drip at a clinic, so you cannot take it at home.
- Infusion reactions and, rarely, allergic reactions can happen, and it is usually only offered after older preventers have been tried.
Practical use
Good to know
It helps to understand the difference between preventers and acute treatments: eptinezumab is a preventer, taken regularly to make migraines less frequent, while you still need a separate medicine to treat an attack when one happens. The anti-CGRP medicines are a newer class developed for people who have not done well with older preventers, so they are usually offered after those have been tried. Because it is a drip, you will need to attend a clinic for each infusion, which takes around half an hour, and you will be watched for any reaction. Benefit is judged over a few months. The main things to be aware of are infusion reactions and, rarely, allergic reactions. It should not be used in pregnancy without specialist advice.
Who should not take it / use with caution
- It should not be used in pregnancy unless a specialist advises, and is best discussed before planning a pregnancy or while breastfeeding.
- People who have had a serious allergic reaction to eptinezumab or its ingredients should not use it.
- It is used with care in people with certain heart or blood-vessel conditions, who should discuss this with their specialist.
Monitoring
- Being watched during and after each infusion for any reaction.
- Reviewing after a few months whether migraines have reduced enough to continue.
- Discussing pregnancy plans, breastfeeding and overall migraine control at review.
Side effects
- Reactions during or shortly after the infusion, such as flushing, a stuffy nose or throat discomfort, can occur.
- Some people get a sore throat or cold-like symptoms, or tiredness.
- Rarely, a more serious allergic reaction can occur, which is why you are watched after the drip.
Key interactions
- It has few known interactions with other medicines, as it works on CGRP rather than being processed like ordinary tablets.
- It can be used alongside acute migraine treatments for attacks, but tell your team about everything you take.
- Always tell your specialist about other preventer medicines so your overall migraine plan can be reviewed.
Available as: A liquid given as a drip (infusion) into a vein at a clinic or hospital.
Answers
Eptinezumab: frequently asked questions
How is eptinezumab different from the other anti-CGRP medicines?
It is given as a drip into a vein every three months at a clinic, rather than as an injection under the skin that you can do at home.
Will it treat a migraine I already have?
No. It is a preventer taken regularly to make migraines less frequent, so you still need a separate acute treatment for an attack that has started.
How often will I need the drip?
It is usually given once every three months, so there are only a few infusions across the year.
Why am I watched after the infusion?
Infusion reactions and, rarely, allergic reactions can happen, so you are observed for a short time afterwards to make sure you are well.
Can I have it in pregnancy?
It should not be used in pregnancy without specialist advice, so discuss it if you are pregnant, planning a pregnancy or breastfeeding.
The wider class
About Anti-CGRP biologic (migraine prevention)
Eptinezumab belongs to the anti-cgrp biologic (migraine prevention) class. For how the class as a whole works, its shared safety principles and monitoring, see the full guide.
Browse by body system
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.